从业绩“深蹲”到全球跃迁：解码仙乐健康的破局逻辑

Core Viewpoint - The health supplement industry in China is transitioning from rapid growth to structural adjustment, with Xianle Health (300791) taking significant steps, including a planned H-share listing, amidst a projected 53% to 69% decline in net profit for 2025 [1] Financial Performance - Xianle Health ranks among the top three globally and first in China in the nutrition health food solutions industry, with revenue expected to grow from 3.582 billion RMB in 2023 to 4.211 billion RMB in 2024, reflecting a 17.6% year-on-year increase [2][3] - The company reported a revenue of 3.291 billion RMB for the first nine months of 2025, showing a 7.96% increase compared to the same period in 2024, indicating a significant slowdown in growth [2] - The gross profit margin improved from 29.65% in 2023 to 30.61% in 2024, and further to 31.48% in the first nine months of 2025, suggesting effective product structure optimization and cost control [4] Profitability Challenges - Net profit saw a dramatic decline, with 2023 net profit at 240 million RMB, increasing to 282 million RMB in 2024, but plummeting to only 55.535 million RMB in the first nine months of 2025 [5] - The company experienced a significant rise in expense ratios, with sales expense ratio increasing to 8.30% and administrative expense ratio to 10.81% in the first nine months of 2025, reflecting increased market expansion costs and decreased operational efficiency [5] Strategic Moves - The decision to pursue an H-share listing is driven by the need for capital during the industry's transition, funding for global expansion, and the establishment of a diversified capital platform [6] - Xianle Health is positioned to benefit from the global nutrition health food solutions market, which is projected to grow from 29.4 billion USD in 2024 to 42.4 billion USD by 2029, at a compound annual growth rate of 7.6% [7] Market Position and Growth Potential - The industry is characterized by a highly fragmented market with a CR5 of only 10.5%, providing opportunities for consolidation by leading companies like Xianle Health [9] - The company has established a global manufacturing network with bases in China, Europe, North America, and Southeast Asia, with a significant investment in a Thai facility aimed at serving the Asia-Pacific market [9] Innovation and Adaptation - Xianle Health is adapting to new consumer channels, with over 50% of revenue coming from social e-commerce and new retail, and has seen a 60% growth in products targeting young female consumers [10] - The company is focusing on core competencies in soft capsules and gummies, which are growing faster than the industry average, establishing a competitive edge in these segments [9]